Oncolys Biopharma Inc represents values of innovation, dedication, and integrity. With a strong corporate philosophy focused on transforming patients' lives through biopharmaceutical advancements, Oncolys Biopharma strives to develop cutting-edge therapies for various medical conditions. The company's commitment to research and development is guided by a vision of improving global health and serving unmet medical needs. Oncolys Biopharma emphasizes collaboration, employing the expertise of talented scientists, clinicians, and industry professionals to drive progress in the field of biotechnology. Through their relentless pursuit of breakthrough treatments, Oncolys Biopharma aims to make a significant impact on patients' lives worldwide.

Oncolys Biopharma Inc is primarily present in Japan and the United States.

Oncolys Biopharma Inc has achieved several significant milestones. One notable milestone is the successful completion of Phase 1 clinical trials for their lead drug candidate. In addition, the company has secured various strategic partnerships and collaborations with renowned institutions and pharmaceutical companies. Oncolys Biopharma Inc's continuous dedication to research and development has resulted in the development of innovative therapies and breakthrough technologies. Moreover, the company's commitment to patient care and safety has led to the acquisition of regulatory approvals for their drug candidates. These achievements underscore Oncolys Biopharma Inc's position as a leader in the biopharmaceutical industry.

Oncolys Biopharma Inc is a leading biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. Established in [year], the company has a rich history in the field of oncology and has made significant contributions towards improving patient outcomes. Oncolys Biopharma Inc focuses on the research, development, and commercialization of novel immunotherapies and targeted therapies. With a dedicated team of experienced scientists and researchers, the company strives to advance the understanding of cancer biology and develop innovative treatments tailored to specific types of cancer. Driven by a commitment to improving the lives of patients, Oncolys Biopharma Inc has established strategic collaborations with global partners to accelerate the development of its pipeline. Through its cutting-edge technologies and ongoing clinical trials, the company aims to revolutionize cancer treatment and bring hope to patients worldwide.

The main competitors of Oncolys Biopharma Inc in the market include companies like XYZ Pharmaceuticals, ABC Therapeutics, and PQR Biotech. These companies also specialize in the development and commercialization of innovative biopharmaceutical products. While Oncolys Biopharma Inc focuses on pioneering novel cancer treatments, its competitors strive to create breakthrough therapies in the field of oncology. As Oncolys Biopharma Inc continues to make advancements in cancer research, it faces competition from these prominent players in the biopharmaceutical industry, who are all working towards improving patient outcomes and addressing unmet medical needs.

Oncolys Biopharma Inc is primarily active in the pharmaceutical industry.

The business model of Oncolys Biopharma Inc revolves around developing innovative solutions for the treatment of cancer. They primarily focus on the research and development of oncolytic virus therapies to target and destroy cancer cells. By utilizing their expertise in biotechnology, Oncolys Biopharma aims to provide effective and safe treatment options to improve the lives of cancer patients. With a strong dedication to advancing oncology treatments, the company strives to make significant contributions in the field of cancer therapeutics. Through their strategic collaborations and clinical trials, Oncolys Biopharma is committed to bringing novel therapies to market and addressing the unmet medical needs of cancer patients.

P/E odnos Oncolys Biopharma iznosi -20,39.

KUV kompanije Oncolys Biopharma iznosi 11,45.

AlleAktien kvalitativni skor za Oncolys Biopharma je 5/10.

očekivana Oncolys Biopharma promet je 1,01 milijardi JPY.

Dobit očekivana Oncolys Biopharma je -567,24 mil. JPY.

Oncolys Biopharma Inc is a biotechnology company focused on researching and developing therapies for cancer. The company is based in Japan and has a branch in the USA.

Oncolys Biopharma isplaćuje dividendu od 0 JPY raspoređenu preko isplata u toku godine.

Dividenda za Oncolys Biopharma trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Oncolys Biopharma je JP3202170001.

WKN od Oncolys Biopharma je A1W94N.

Oznaka za praćenje akcija kompanije Oncolys Biopharma je 4588.T.

U poslednjih 12 meseci, Oncolys Biopharma je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Oncolys Biopharma će verovatno isplatiti dividendu od 0 JPY.

Dividendski prinos od Oncolys Biopharma trenutno iznosi .

Oncolys Biopharma isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Oncolys Biopharma je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 JPY. To odgovara dividendnom prinosu od 0 %.

Oncolys Biopharma se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Oncolys Biopharma od 24. 10. 2024. u iznosu od 0 JPY, morali ste da imate akciju u depou pre Ex-dana 24. 10. 2024..

Isplata poslednje dividende izvršena je 24. 10. 2024..

U godini 2023 kompanija Oncolys Biopharma je isplatila 0 JPY kao dividende.

Dividende od Oncolys Biopharma se isplaćuju u JPY.